

MAY 3, 2011

Keynote Presentation

8:30 – 9:15 (8:30 am – 9:15 am)

Isaac Witz (Tel Aviv, Israel)

Metastasis and the metastatic microenvironment – the case of neuroblastoma and melanoma

PLENARY SESSION 2

9:20 – 11:25 (9:20 am – 11:25 am)

Regulatory and effector mechanisms in the tumor environment

Chair: Isaac Witz (Tel Aviv, Israel)

Chair: Francesco Marincola (Bethesda, USA)

Alessandra Cesano (San Francisco, USA)

Insight into autoimmune and malignant diseases via Single Cell Network Profiling

Elena Voronov (Beer Sheva, Israel)

Differential role of IL-1 alpha and beta in inflammation and cancer

Suzanne Ostrand-Rosenberg (Baltimore, USA)

Immune suppression in the tumor microenvironment

Luca Vannucci (Prague, Czech Rep)

Stroma-proinflammatory elements cross-talk can functionally shape tissue structures influencing the tumor microenvironment

Olga Aprelikova (Bethesda, USA)

MicroRNA regulation in cancer-associated fibroblasts

Special Plenary Presentations 1 11:30 – 12:30 (11:30 am – 12:30 pm)

New insights in cancer immunotherapy

Chair: Tom Sayers (Frederick, USA)

Chair: Viktor Umansky (Heidelberg, Germany)

Galina V. Shurin (Pittsburgh, USA)

Regulatory dendritic cells in cancer

Beatrix Kotlan (Budapest, Hungary)

Tumor antigen recognition by B cells in melanoma

Natalia Aptsiauri (Granada, Spain)

Immune escape and resistance to immunotherapy of tumor cells with the beta2m gene alterations in recurrent melanoma metastases

Alexandra Sevko (Heidelberg, Germany)

Absence of antitumor effect of low-dose cyclophosphamide in ret-transgenic mice due to the accumulation of myeloid derived suppressor cells

S.M. Mansour Haeryfar (London, Canada)

Rapamycin differentially modulates anticancer and alloreactive CD8+ T cell responses generated in the same host

Lunch break

12:30 – 13:30 (12:30 pm – 1:30 pm)

PLENARY SESSION 3

13:30 – 15:35 (1:30 pm – 3:35 pm)

Tumor microenvironment and cancer immunotherapy

Chair: Suzanne Ostrand-Rosenberg (Baltimore, USA)

Chair: Graham Pawelec (Tübingen, Germany)

Arthur Hurwitz (Frederick, USA)

Identifying immunosuppressive targets in prostate cancer to enhance T cell responses

Theresa Whiteside (Pittsburgh, USA)

Disarming suppressor cells to improve cancer immunotherapy

Licia Rivoltini (Milan, Italy)

Targeting tumor-related immunosuppression in cancer patients

Michal Baniyash (Jerusalem, Israel)

Chronic inflammation-induced immunosuppression: Underlying mechanisms and clinical implications for cancer therapy

Éva Rajnavölgyi (Debrecen, Hungary)

Dendritic cell subsets as targets of anti-tumor immunotherapies

Coffee break (20 min)

PLENARY SESSION 4

15:55 – 18:00 (3:55 pm – 6:00 pm)

Improving cancer immunotherapy: New targets, vaccines and models

Chair: Ron Apte (Beer Sheva, Israel)

Chair: Licia Rivoltini (Milan, Italy)

Federico Garrido (Granada, Spain)

“Hard” and “Soft” lesions underlying HLA Class I alterations in cancer cells: Implications for cancer immune escape and immunotherapy

Zoltán Szekanecz (Debrecen, Hungary)

Common targets of anti-cancer and anti-inflammatory therapy

Anahid Jewett (Los Angeles, USA)

Natural Killer cells preferentially target Cancer Stem Cells; Role of Monocytes in protection against NK cell mediated lysis of Cancer Stem Cells

Paolo A. Ascierto (Naples, Italy)

Immunomodulating antibodies in treatment of melanoma patients: What's new?

Angel Porgador (Beer Sheva, Israel)

Cancer-associated nuclear factors as ligands to NK receptors

18:15 – 20:15 (6:15 pm – 8:15 pm)

Special Budapest overview sightseeing tour for CITIM 2011 participants

MAY 4, 2011

Keynote Presentation

8:30 – 9:15 (8:30 am – 9:15 am)

Malcolm Brenner (Baylor College of Medicine, Houston, TX, USA)

Developing Gene modified T cells as effective agents for cancer treatment

PLENARY SESSION 5

9:20 – 11:00 (9:20 am – 11:00 am)

Immunotherapeutic approached to pediatric malignancies

Chair: Leonid Metelitsa (Houston, USA)

Chair: Laurence Cooper (Houston, USA)

Gianpietro Dotti (Houston, USA)

CAR-modified T cells for immunotherapy: enhancement of persistence and trafficking

Leonid Metelitsa (Houston, USA)

Localization and Function of NKT cells in Neuroblastoma

John Anderson (London, UK)

Human gamma delta T cells in cancer immunotherapy; killing and cross presenting functions

Laurence Cooper (Houston, USA)

First-in-human application of transposon/transposase system to generate T cells to target malignant B cells

Special Plenary Presentations 2 11:05 – 12:25 (11:05 am – 12:25 pm)

New aspects of immune regulation

Chair: Allesandra Cesano (San Francisco, USA)

Chair: Paolo A. Ascierto (Naples, Italy)

Eva Klein (Stockholm, Sweden)

Lymphokines can modify the expression of EBV encoded proteins in B lymphocytes

Laszlo G. Radvanyi (Houston, USA)

Melanoma, T regulatory cells, ICOS and IL-2 therapy: What's the connection?

Georgi Guruli (Richmond, USA)

The effect of endothelin axis on the function of murine dendritic cells

Adit Ben-Baruch (Tel Aviv, Israel)

The inflammatory network of cytokines & chemokines in breast cancer: Effects on epithelial-to-mesenchymal transition and beyond

Lunch break 12:25 – 13:25 (12:25 pm – 1:25 pm)

POSTER SESSION

13:30 – 14:50 (1:30 pm – 2:50 pm)

Special Presentation:

"The quality of life potentials of CERAGEM in health and disease" (13:30 – 14:00, conference room)

PLENARY SESSION 6

14:50 – 16:55 (2:50 pm – 4:55 pm)

Cancer immunotherapy: Lessons and perspectives

Chair: Hideho Okada (Pittsburgh, USA)

Chair: Claude Leclerc (Paris, France)

Eitan Yefenof (Jerusalem, Israel)

The molecular rationale of steroid based therapy

Perthor Straten (Herlev, Denmark)

CD8 T cells in cancer: killers, supporters and suppressors

Jonathan Weiss (Frederick, USA)

Re-structuring tumor/tissue microenvironments by IL-12-dependent interventions

Jozsef Timar (Budapest, Hungary)

Identification and clinical validation of an IFN-resistance gene signature of human melanoma

Nechama Haran-Ghera (Rehovot, Israel)

Chemoimmunotherapy reduces the progression of multiple myeloma: Implication for maintenance therapy

Coffee break (25 min)

PLENARY SESSION 7

17:20 – 19:00 (5:20 pm – 7:00 pm)

Cancer immunotherapy: Regulatory and effector cell interactions

Chair: Eva Klein (Stockholm, Sweden)

Chair: Gurkamal Chatta (Pittsburgh, USA)

Graham Pawelec (Tübingen, Germany)

Immune signatures in long-term melanoma survivors

Claude Leclerc (Paris, France)

Comparative repertoire analysis of tumor infiltrating Effector and Regulatory CD4+ T cells

Benjamin Sredni (Ramat Gan, Israel)

Interference with VLA4 and Microenvironmental Interactions by the Tellurium Compound AS101 Results in the Sensitization of AML Cells to Chemotherapy

Viktor Umansky (Heidelberg, Germany)

Overcoming tumor-induced immunosuppression in ret transgenic mouse melanoma model

MAY 5, 2011

Keynote Presentation

8:30 – 9:15 (8:30 am – 9:15 am)

William Murphy (Sacramento, USA)

Bystander memory T cell activation after immunotherapy: how much do we need antigen-specific responses in cancer?

PLEANARY SESSION 8

9:20 – 11:25 (9:20 am – 11:25 am)

Cancer immunotherapy: New approaches

Chair: Anatoli Malyguine (Frederick, MD, USA)

Chair: Paul Lehmann (Shaker Heights, OH, USA)

Michael R. Shurin (Pittsburgh, USA)

Targeting immune regulators in the tumor microenvironment

Udo S. Gaipl (Erlanger, Germany)

Ex vivo and in vivo induced dead tumor cells as modulators of anti-tumor responses

Ramon Kaneno (Botucatu, Brazil)

Development of dendritic cell vaccines for colon cancer

Barbara Seliger (Halle, Germany)

Novel insights into the modulation of MHC class I antigen processing molecules in tumors

Hideho Okada (Pittsburgh, USA)

Promotion of type-1 response for effective brain tumor immunotherapy

Special Presentations 3: Best Abstract Awards 11:30 – 12:30 (11:30 am – 12:30 pm)

Chair: Laurence Cooper (Houston, USA)

Chair: Arthur A. Hurwitz (Frederic, USA)

Ryu-Ichiro Hata (Yokosuka, Japan)

Production of transgenic mice resistant to cancer cell growth and metastasis

Galina Kaseko (Eveleigh, Australia)

An efficient method of immortalising rare tumour infiltrating B lymphocytes for identification of natural tumour specific antibody repertoire

Flavio Salazar-Onfray (Santiago, Chile)

Immunological and clinical outcomes of a new DC-based vaccine

Gerty Schreibelt (Nijmegen, The Netherlands)

Vaccination of melanoma patients with monocyte-derived dendritic cells matured with commonly used prophylactic vaccines

Fabrizio Mattei (Rome, Italy)

IRF-8 controls melanoma progression by regulating cancer and immune cell cross-talk within the tumor microenvironment

Lunch break

12:30 – 13:30 (12:30 pm – 1:30 pm)

PLENARY SESSION 9
Novel cancer vaccines in clinical trials

13:30 – 15:20 (1:30 pm – 3:20 pm)

Chair: Theresa Whiteside (Pittsburgh, USA)
Chair: Barbara Seliger (Halle, Germany)

Gurkamal S. Chatta (Pittsburgh, USA)
Prostate cancer vaccines

Thomas Sayers (Frederick, USA)
Combining molecular targeting and immunotherapy in cancer

Mepur H. Ravindranath (Los Angeles, USA)
HLA class Ia and HLA-E antibodies in melanoma patients: Response to autologous vaccines

Yehuda Shoenfeld (Tel-Hashomer, Israel)
IVIG – harnessing the innate immune system to counter act autoimmunity and cancer

Special presentation and case report:

Tibor Hajto and **Angelika Kirsch** (Budapest, Hungary)
Immunomodulatory therapy with mistletoe lectins and mistletoe extracts: Preclinical and clinical data

Coffee break (25 min)

PLENARY SESSION 10 16:00 – 17:40 (4:00 pm – 5:40 pm)
Novel cancer vaccines and immunomonitoring in clinical trials

Chair: Luca Vannucci (Prague, Czech Rep)
Chair: William Murphy (Sacramento, USA)

Ulrich Hoffmüller (Berlin, Germany)
Immunomonitoring using Epigenetic qPCR Assays

Luigi Buonaguro (Naples, Italy)
Ex vivo analysis of idiotypic vaccine for HCV-related lymphoproliferative disorders

Paul V. Lehmann (Shaker Heights, USA)
Reasons for discrepancy in T cell monitoring data and clinical outcome: epitope spreading, T cell avidity and effector class

Special Selected Short Presentation:

Erik Aarntzen (Nijmegen, The Netherlands)
Skin-test infiltrating lymphocyte (SKIL) analysis adequately predict clinical outcome upon DC vaccination in metastatic melanoma patients

Anatoli M. Malyguine (Frederick, USA)
Monitoring CTL activity in cancer vaccine clinical trials

CONCLUDING REMARKS AND CONFERENCE CLOSING

BANQUET (sponsored by CERAGEM)